Sitemap| Cellceutix Announces Acquisition of New Compound |
|
B14 - October 2, 2009 - INDIA-WEST BEVERLY, Mass. - The Cellceutix Corporation announced Aug. 25 that it has acquired the rights to the compound KM 732, which shows properties in the reduction of high blood pressure, according to a press release. KM 732 is a small molecule that was developed in a Cellceutix-af-filiated laboratory in Pune. The compound will now be synthe-sized in the U.S. "We believe that one of our strengths as a company is our ability to find new and medically useful compounds to strengthen our pipeline,"said Cellceutix CEO George Evans. "Hypertensive emergency is a serious condition affecting over 500,000 Americans per year, thus warranting our early investigational efforts into KM732." In other news, Cellceutix announced recently that it success-fully completed a series of animal model tests on two multi-drug resistant tumors using the com-pound Kevetrin. In each cell line, tumor volume was reduced by more than 90 percent and tumor growth was delayed by more than 100 percent. "These results suggest promis-ing development potential for Kevetrin considering that current treatment options for these multi-drug resistant cell lines are limited in their effectiveness," said Cell-ceutix president Krishna Menon. "Not since my work on Alimta and Gemzar at Lilly have I been this excited about a compound." |